Disease Landscape and Forecast Insights

Using national patient-level claims data, this report analyzes physician adherence to the treatment guidelines by exploring the use of key therapies in the newly diagnosed and recently treated…

Scleroderma (systemic sclerosis [SSc]) is a rare progressive autoimmune disease characterized by skin fibrosis and varying degrees of vasculopathy manifesting as Raynaud’s disease and, often,…

Consolidation within the oncology provider community, including hospital acquisitions of oncology practices and oncology practices joining together, is changing the dynamics in the relationship…

Idiopathic pulmonary fibrosis (IPF), although a rare disease, is one of the most common interstitial lung diseases (ILDs) and is characterized by irreversible loss of lung function leading to high…

Gram-Negative Infections | Access & Reimbursement | US examines the market access factors that influence commercial success of therapies for the treatment of gram-negative infections. The analysis…

Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma in the EU5 and a common indication for liver transplantation. The 2013-2015 EMA…

From disease basics to insightful analysis of market dynamics, Glioma | Disease Landscape & Forecast | United States, EU5 provides comprehensive disease coverage addressing critical aspects of the…

The acute migraine market is dominated by the oral triptans, although genericization of these agents as well as approvals in recent years of multiple non-oral triptans and non-triptans have begun…

The uptake of biosimilar erythropoiesis-stimulating agents (ESAs) varies from country to country, as well as by drug and manufacturer. European nephrologists have been able to prescribe ESAs to…

The systemic lupus erythematosus (SLE) market in the United States is largely genericized and off-label. With the exception of Benlysta (IV)—which launched in 2011—no new drug has been approved…

The HIV therapy market is growing as a result of the uptake of new premium-priced antiretroviral agents, particularly the latest single-tablet regimens (STRs) with improved side-effect profiles…

The Current Treatment Bone and Mineral Metabolism (BMM) disorders content examines the management of dialysis and mid- to late-stage chronic kidney disease (CKD) patients from the perspective of…